ライフサイエンスコーパス: insulin-like growth factor

1 ng roles for cancer progression, such as the insulin-like growth factors.

2 itro, resulting in higher bioavailability of insulin-like growth factors.

3 sociates with abrogation of a growth hormone/insulin-like growth factor 1 (GH/IGF1) axis.

4 To determine the roles of insulin and insulin-like growth factor 1 (IGF-1) action in adipose t

5 ric dysfunction (EED) and disturbance of the insulin-like growth factor 1 (IGF-1) axis.

6 igitumumab, an anticancer drug that prevents insulin-like growth factor 1 (IGF-1) from binding to its

7 Human insulin-like growth factor 1 (IGF-1) is a 70 amino acid

8 Insulin-like Growth Factor 1 (IGF-1) is associated with

9 Insulin-like growth factor 1 (IGF-1) is known to have di

10 mones and neuropeptides, such as insulin and insulin-like growth factor 1 (IGF-1) likely modulate gly

11 spective case-control studies suggested that insulin-like growth factor 1 (IGF-1) or insulin-like gro

12 t or energy levels-most notably, the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway,

13 nction through the regulation of the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway.

14 liferation by modulating a decrease in serum insulin-like growth factor 1 (IGF-1) that allows GH rele

15 f the pro-osteoclastogenic factors RANKL and insulin-like growth factor 1 (IGF-1) to induce osteoclas

16 Finally, we studied the impact of insulin-like growth factor 1 (IGF-1) treatment on CDKL5

17 anismal level as shown by down-regulation of insulin-like growth factor 1 (IGF-1), a hallmark of prem

18 Serum levels of insulin-like growth factor 1 (IGF-1), a hormone with kno

19 pe 2 diabetes mellitus (T2DM) via binding of insulin-like growth factor 1 (IGF-1), an insulin-like ho

20 ng serum concentrations of glucose, insulin, insulin-like growth factor 1 (IGF-1), insulin-like growt

21 schistosome-infected pregnancies, including insulin-like growth factor 1 (IGF-1), tumor growth facto

22 We previously established that an insulin-like growth factor 1 (IGF-1)-inducible mitochond

23 n-associated cytokines, macrophages released insulin-like growth factor 1 (IGF-1).

24 y, and low circulating levels of insulin and insulin-like growth factor 1 (IGF-1).

25 ress osteopontin (OPN) and receptors for the insulin-like growth factor 1 (IGF-1).

26 gate (MTA) showed an increased expression of insulin-like growth factor 1 (IGF-1).

27 +DE patient serum revealed altered levels of insulin-like growth factor 1 (IGF-I) and its binding pro

28 o-expression of two soluble proteins, namely insulin-like growth factor 1 (IGF1) and osteopontin (OPN

29 Insulin-like growth factor 1 (IGF1) and phosphoinositol

30 ingly, treatment of RTT-derived neurons with Insulin-like Growth Factor 1 (IGF1) could rescue some of

31 ain-derived neurotrophic factor that affects insulin-like growth factor 1 (IGF1) expression in Mecp2(

32 Insulin-like growth factor 1 (IGF1) has potent trophic e

33 novel MALDImmunoassay for quantification of insulin-like growth factor 1 (IGF1) in human plasma.

34 osensor for the determination of the hormone insulin-like growth factor 1 (IGF1) is reported for the

35 Insulin-like growth factor 1 (IGF1) is secreted in an au

36 receptor tyrosine kinases by neuregulin and insulin-like growth factor 1 (IGF1) leads to the phospho

37 ic species with high binding affinity to the insulin-like growth factor 1 (IGF1) receptor.

38 ffects of (56)Fe radiation on adipokines and insulin-like growth factor 1 (IGF1) signaling axis in mo

39 toxic inflammation, increases cytoprotective insulin-like growth factor 1 (IGF1) signaling, and preve

40 epithelium fate by regulating apoptosis and insulin-like growth factor 1 (IGF1) signaling.

41 Human fibroblast growth factor 2 (FGF2) and insulin-like growth factor 1 (IGF1), are canonical proto

42 reased cellular sensitivity to estradiol and insulin-like growth factor 1 (IGF1), as measured in grow

43 or muscle growth, including the induction of insulin-like growth factor 1 (IGF1), as well as concomit

44 ted sites cluster on the binding surfaces of insulin-like growth factor 1 (IGF1), IGF1 receptor (IGF1

45 n, or co-overexpression of osteopontin (OPN)/insulin-like growth factor 1 (IGF1)/ciliary neurotrophic

46 cer pinpoint to a potential new function for insulin-like growth factor 1 (Igf1r) in the basal epithe

47 Drugs that inhibit insulin-like growth factor 1 (IGFI) receptor IGFIR were

48 growth hormone concentration >2.5 mug/L and insulin-like growth factor 1 [IGF-1] concentration >1.3

49 Insulin-like growth factor 1 activated the phosphoinosit

50 ands, and feet and are diagnosed by elevated insulin-like growth factor 1 levels and growth hormone l

51 and fibrin extracellular matrix proteins and insulin-like growth factor 1 on the force production of

52 Supplementation of insulin-like growth factor 1 partially reverted the DR-i

53 the insulin receptor (F-IRKO) or both IR and insulin-like growth factor 1 receptor (F-IR/IGFRKO).

54 atric skin display reduced activation of the insulin-like growth factor 1 receptor (IGF-1R) and alter

55 iates for the activation of PI3K by both the insulin-like growth factor 1 receptor (IGF-1R) and its c

56 Here, we found in the mouse that the insulin-like growth factor 1 receptor (IGF-1R) controls

57 rs revealed 6ha as preferential inhibitor of insulin-like growth factor 1 receptor (IGF-1R) in a pane

58 We have previously shown that the insulin-like growth factor 1 receptor (IGF-1R) transloca

59 tor 2 (IGF2) gene, encoding a ligand for the insulin-like growth factor 1 receptor (IGF-1R), in a sub

60 ession in this lineage and was stimulated by insulin-like growth factor 1 receptor (IGF1R) activation

61 in asthma, but little is known about how the insulin-like growth factor 1 receptor (IGF1R) affects as

62 s determined that LMP1 selectively activates insulin-like growth factor 1 receptor (IGF1R).

63 ang et al that describes a critical role for insulin-like growth factor 1 receptor in the progression

64 s as an autocrine activator of the beta-cell insulin-like growth factor 1 receptor signaling pathway.

65 2 (Cyclin D2), CCND1 (Cyclin D1), and IGF1R (insulin-like growth factor 1 receptor) genes involved in

66 t-mammalian target of rapamycin pathway, and insulin-like growth factor 1 receptor-targeted therapy h

67 apoptosis and liver injury by targeting the insulin-like growth factor 1 receptor.

68 gans strains with mutations in daf-2/insulin/insulin-like growth factor 1 receptor.

69 ate 1 (IRS1), a component of the insulin and insulin-like growth factor 1 signaling pathway.

70 hanges in microRNA levels regulate SIRT1 and insulin-like growth factor 1 signalling.

71 story, medications, and laboratory findings (insulin-like growth factor 1, follicle-stimulating hormo

72 eased expression of pro-regenerative factors insulin-like growth factor 1, leukemia inhibitory factor

73 yotube hypertrophy through the expression of insulin-like growth factor 1, which is dependent on Galp

74 pinal cord, and normalization of circulating insulin-like growth factor 1.

75 model assessment of insulin resistance, and insulin-like growth factor 1.

76 ation but instead sustained signaling of the insulin-like growth factor 1/phosphatidylinositol 3-kina

77 However, the possible roles of the insulin like growth factor-1 receptor (IGF-1R) on neuron

78 growth while suppressing the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

79 entified dysregulation of the Growth Hormone/Insulin-like Growth Factor-1 (GH/IGF-1) pathway as well

80 In addition to IRBP, the IPM also contains insulin-like growth factor-1 (IGF-1) and its associated

81 scular endothelial growth factor-A (VEGF-A), insulin-like growth factor-1 (IGF-1) and Klotho, in the

82 Insulin-like growth factor-1 (IGF-1) and signal transduc

83 recurrent GBM, driven by macrophage-derived insulin-like growth factor-1 (IGF-1) and tumor cell IGF-

84 e previously shown that systemic infusion of insulin-like growth factor-1 (IGF-1) exerts anti-inflamm

85 (PFNA), may alter levels of sex hormones and insulin-like growth factor-1 (IGF-1) in animals.

86 Our earlier studies showed that insulin-like growth factor-1 (IGF-1) increases collagen

87 Exogenous Insulin-Like Growth Factor-1 (IGF-1) is neuroprotective

88 eurons, have triggered a renewed interest in insulin-like growth factor-1 (IGF-1) pathway activation

89 e MC4R, we assessed pulsatile GH release and insulin-like growth factor-1 (IGF-1) production and/or r

90 Activation of insulin-like growth factor-1 (IGF-1) receptor (IGF1R) si

91 In contrast, mice pretreated with insulin-like growth factor-1 (IGF-1) showed resolution o

92 atory pathway for E2F-2 production involving insulin-like growth factor-1 (IGF-1) signaling is simult

93 mediates adipogenesis and show a link to the insulin-like growth factor-1 (IGF-1) signaling pathway.

94 ells secrete a subthreshold concentration of insulin-like growth factor-1 (IGF-1) that primes the IGF

95 Insulin-like growth factor-1 (IGF-1), a small protein/po

96 ce (95% CI) was computed for levels of serum insulin-like growth factor-1 (IGF-1), leptin, and adipon

97 elaborates the cardioprotective polypeptide, insulin-like growth factor-1 (IGF-1), which activates IG

98 resistance leading to low concentrations of insulin-like growth factor-1 (IGF-1); relative hypercort

99 n epidermal growth factor receptor (HER) and insulin-like growth factor-1 (IGF-1R) family of receptor

100 When insulin-like growth factor-1 (IGF1) binds to its recepto

101 Here, we show that insulin-like growth factor-1 (IGF1) levels are reduced i

102 ical stimulation that significantly promoted insulin-like growth factor-1 (IGF1) production and elici

103 ion and proliferation as well as insulin and insulin-like growth factor-1 (IGF1) receptor activation

104 eration, the expression of cellular insulin, insulin-like growth factor-1 (IGF1), and GHRH receptor,

105 actors released by astrocytes as insulin and insulin-like growth factor-1 (IGF1).

106 secretion of paracrine mediators, including insulin-like growth factor-1 (IGF1).

107 ained only a modest amount of variability in insulin-like growth factor-1 and insulin-like growth fac

108 tress syndrome were strongly associated with insulin-like growth factor-1 and insulin-like growth fac

109 Total insulin-like growth factor-1 and insulin-like growth fac

110 ignificantly influence circulating levels of insulin-like growth factor-1 and insulin-like growth fac

111 , SP and its metabolites in combination with insulin-like growth factor-1 are shown to promote the co

112 Perfluoroalkyl substances, sex hormones, and insulin-like growth factor-1 at 6-9 years of age: a cros

113 Evaluation III was strongly associated with insulin-like growth factor-1 levels; and age was strongl

114 TRPC6 complementation and by treatment with insulin-like growth factor-1 or hyperforin, a TRPC6-spec

115 The insulin-like growth factor-1 pathway was activated to a

116 Elevated IGF-1/insulin-like growth factor-1 receptor (IGF-1R) autocrine

117 In the present study, we report that insulin-like growth factor-1 receptor (Igf-1r) gene expr

118 Increased expression or signaling from the insulin-like growth factor-1 receptor (IGF-1R) has been

119 abolished these effects of insulin, whereas insulin-like growth factor-1 receptor (IGF-1R) silencing

120 nockdown by RNAi decreased expression of the insulin-like growth factor-1 receptor (IGF-1R), resultin

121 The insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are highly

122 -regulation of two of its targets: BCL-2 and insulin-like growth factor-1 receptor (IGF1R).

123 P-REX1 also promoted insulin-like growth factor-1 receptor activation, sugges

124 e, telomere length, telomerase activity, and insulin-like growth factor-1 receptor expression were me

125 pointed to the insulin-like growth factor-1-insulin-like growth factor-1 receptor system as a major

126 mmunohistochemical positivity for p4E-BP1 or insulin-like growth factor-1 receptor was statistically

127 ulted in downregulation of lipoxygenases and insulin-like growth factor-1 receptor.

128 Treatment with recombinant human insulin-like growth factor-1 restores responses of PV(+)

129 Impaired insulin/insulin-like growth factor-1 signalling (IGF-1) and insu

130 The high concentration of insulin-like growth factor-1 systemically pointed to the

131 2 saturation and plasma glucose, insulin and insulin-like growth factor-1 were positively associated

132 ccumulation, which was confirmed in vitro as insulin-like growth factor-1, a known mediator of physio

133 ich was amplified by MCL-specific cytokines (insulin-like growth factor-1, B-cell activating factor,

134 as well as four long-lived mutants (insulin/insulin-like growth factor-1, dietary restriction, prote

135 nel of serologic testing that included serum insulin-like growth factor-1, insulin-like growth factor

136 changes including altered levels of insulin, insulin-like growth factor-1, leptin, adiponectin, stero

137 -1 and AKT following stimulation by insulin, insulin-like growth factor-1, or the neurotrophins (NGF

138 This potentiation is produced by insulin-like growth factor-1, whose binding proteins are

139 growth factor-1 systemically pointed to the insulin-like growth factor-1-insulin-like growth factor-

140 emoattractant protein-1, IL-6, IL-1beta, and insulin-like growth factor-1.

141 of growth factors such as interleukin-6 and insulin-like growth factor-1.

142 Adaptor proteins in the insulin/insulin-like-growth factor-1 signaling pathways, such as

143 w this control is abrogated by inhibition of insulin-like growth factor-1R/INSR-driven phosphoinositi

144 nockdown cells was associated with increased insulin-like growth factor- 1Rbeta (IGF-1Rbeta) levels.

145 The human insulin-like growth factor 2 (IGF2) and insulin genes ar

146 mouse hippocampus, induces the expression of insulin-like growth factor 2 (IGF2) for the stabilizatio

147 s Network detected the overexpression of the insulin-like growth factor 2 (IGF2) gene, encoding a lig

148 The H19/insulin-like growth factor 2 (Igf2) ICR has a multifunct

149 We addressed this question at the H19/insulin-like growth factor 2 (Igf2) imprinted locus, the

150 Insulin-like growth factor 2 (IGF2) is the major fetal g

151 IMPs, also known as insulin-like growth factor 2 (IGF2) messenger RNA (mRNA)

152 RNA-binding proteins of the IMP family (insulin-like growth factor 2 (IGF2) mRNA-binding protein

153 t that Hh markedly induces the expression of insulin-like growth factor 2 (Igf2) that activates the m

154 activating enzyme, deiodinase-III (Dio3) and insulin-like growth factor 2 (Igf2), genes that are know

155 Insulin-like growth factor 2 (IGF2), produced and secret

156 he expression of several myokines, including insulin-like growth factor 2 (IGF2), whereas RNAi and do

157 Loss of SRSF3 increases expression of insulin-like growth factor 2 and the A-isoform of the in

158 The gene encoding the Insulin-like Growth Factor 2 mRNA binding protein 2/IMP2

159 f the heterochronic let-7 miRNA pathway, the insulin-like growth factor 2 mRNA-binding protein 1 (IGF

160 Here, we determined that the RBP insulin-like growth factor 2 mRNA-binding protein 3 (IGF

161 ion in mutants exhibiting aberrant H19/Igf2 (insulin-like growth factor 2) imprinting.

162 iation [RalGDS/AF-6] domain family member 1, insulin-like growth factor 2, and adenomatous polyposis

163 or necrosis factor alpha and lower levels of insulin-like growth factor 2.

164 he growth-promoting and mitogenic effects of insulin-like growth factor 2.

165 ts known ability to promote the abundance of Insulin-like Growth Factor 2/IGF2, we find that IMP2 str

166 Higher levels of apoptosis, reduced insulin-like growth factor-2 expression, and altered ant

167 IMP3 (insulin-like growth factor-2 mRNA binding protein 3) is

168 The insulin-like growth factor-2 mRNA-binding protein 1 (IGF

169 acellular domains of the mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF2R), domai

170 xpression of the trophoblast survival factor insulin-like growth factor-2 was significantly lower.

171 3 as a dominant driver oncogene at the IGF2 (insulin-like growth factor-2) 11p15.5 CRC amplicon, indu

172 , other hormonal mediators such as dopamine, insulin-like growth factor, and angiotensin II also affe

173 ssays revealed targets of miR-145 within the insulin-like growth factor axis.

174 ing indicated substantial down-regulation of insulin-like growth factor binding protein (Igfbp) genes

175 Insulin-like growth factor binding protein (IGFBP)-1 inf

176 tor (PDGF) isoforms (PDGF-AA, -BB, and -AB), insulin-like growth factor binding protein (IGFBP)-2, an

177 Low circulating levels of insulin-like growth factor binding protein 1 (IGFBP-1) a

178 Insulin-like growth factor binding protein 1 (IGFBP-1) i

179 Insulin-like growth factor binding protein 2 (IGFBP2) is

180 that insulin-like growth factor 1 (IGF-1) or insulin-like growth factor binding protein 3 (IGFBP-3) w

181 sulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3),

182 K regulates Runx1-dependent transcription of insulin-like growth factor binding protein 3 (IGFBP3), a

183 -1, cartilage oligomeric matrix protein, and insulin-like growth factor binding protein 7 concentrati

184 Cartilage oligomeric matrix protein, insulin-like growth factor binding protein 7, and beta-g

185 In this setting, the insulin-like growth factor binding protein IGFBP7 inhibi

186 ide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2) and 5 clin

187 ide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2.

188 Reduction of prolactin, insulin-like growth factor binding protein-3, and matrix

189 included serum insulin-like growth factor-1, insulin-like growth factor binding protein-3, prolactin,

190 atocyte growth factor, endocrine gland VEGF, insulin-like growth factor binding proteins, or endostat

191 d hepatocyte nuclear factor (HNF) 4alpha and insulin-like growth factor-binding protein (IGFBP) 1 mRN

192 Binding of STC2 prevents PAPP-A cleavage of insulin-like growth factor-binding protein (IGFBP)-4 and

193 esponse elements located in the promoters of insulin-like growth factor-binding protein 1 (IGFBP1) an

194 anges in microglial secretome and identified insulin-like growth factor-binding protein 1 (IGFBP1) as

195 everal genes, e.g., Sonic hedgehog (Shh) and Insulin-like growth factor-binding protein 2 (Igfbp2), t

196 Higher levels of insulin-like growth factor-binding protein 3 (IGFBP-3) m

197 The regulation of insulin-like growth factor-binding protein 3 (IGFBP3) ge

198 eracts with the promoter of IGFBP5 (encoding insulin-like growth factor-binding protein 5) and displa

199 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 accurately

200 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in patients

201 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in this pop

202 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 results in

203 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 significant

204 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 test was no

205 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was 0.84 (0

206 owed by a marker of cell cycle arrest (urine insulin-like growth factor-binding protein 7) and, final

207 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7.

208 g levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 early in cr

209 854746 is also significantly associated with insulin-like growth factor-binding protein-3 levels in t

210 ciated with insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 levels; Acu

211 Total insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 were measur

212 iability in insulin-like growth factor-1 and insulin-like growth factor-binding protein-3.

213 levels; and age was strongly associated with insulin-like growth factor-binding protein-3.

214 746 was significantly associated with plasma insulin-like growth factor-binding protein-3.

215 cancer model and decreased the expression of insulin-like growth factor-binding protein-5 (IGFBP5).

216 n complex ways in osteoblasts, converging on insulin like growth factor I (IGF-I) expression.

217 Insulin and insulin-like growth factor I (IGF-I) signal through the

218 Disruption of insulin-like growth factor I (IGF-I) signaling is a key

219 AD in mice responds positively to decreased insulin-like growth factor I (IGF-I) signaling, a pathwa

220 mini nutritional assessment (P = 0.003), and insulin-like growth factor I (P = 0.002), and lowered C-

221 d tumor necrosis factor receptor 1 and lower insulin-like growth factor I and leptin.

222 ED decreased serum insulin-like growth factor I concentrations and increase

223 Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new

224 onal immunoglobulin G1 antibody that targets insulin-like growth factor I receptor (IGF-IR).

225 ved growth factor receptor beta (Pdgfrb) and insulin-like growth factor I receptor (Igf1r) on T-ALL c

226 erum IL-6, tumor necrosis factor receptor 1, insulin-like growth factor I, and leptin.

227 human epidermal growth factor, insulin, and insulin-like growth factor I, particularly at the parasi

228 bolic variables, including glucose, insulin, insulin-like growth factor I, triglycerides, cholesterol

229 Insulin and insulin-like growth factors I and II are closely related

230 GFBP)-1 influences fetal growth by modifying insulin-like growth factor-I (IGF-I) bioavailability.

231 l and neuropsychological recovery, and serum insulin-like growth factor-I (IGF-I) may mediate this ef

232 In the total population, insulin-like growth factor-I (IGF-I)-enhanced cell cycle

233 Growth-related glycoproteins insulin-like growth factor (IGF) 1, IGF binding protein-

234 The insulin-like growth factor (IGF) axis may be implicated

235 however, data on mutations in IGF2, encoding insulin-like growth factor (IGF) II, are lacking.

236 stoma, is driven by Sonic hedgehog (Shh) and insulin-like growth factor (IGF) in the developing cereb

237 Signaling via the insulin-like growth factor (IGF) pathway is aberrantly a

238 The insulin-like growth factor (IGF) receptor (IGF-IR) is ne

239 Lowered insulin/insulin-like growth factor (IGF) signaling (IIS) can ext

240 the sirtuin family of proteins, the insulin/insulin-like growth factor (IGF) signaling (IIS) pathway

241 D) progression is significantly delayed when insulin-like growth factor (IGF) signaling is blocked in

242 The insulin/insulin-like growth factor (IGF) signaling pathway plays

243 Insulin-like growth factor (IGF) signaling plays an impo

244 d plasma protein-A (PAPP-A), which modulates insulin-like growth factor (IGF) signaling through prote

245 study is the identification of mutations in insulin-like growth factor (IGF) signalling genes in 8/1

246 The insulin-like growth factor (IGF) system is a well-studie

247 .0001), insulin (r(2) = 0.40, P < 0.005) and insulin-like growth factor (IGF)-1 (r(2) = 0.80, P < 0.0

248 The insulin/insulin-like growth factor (IGF)-1 signaling pathway (IS

249 AT3 phosphorylation by interleukin-6 (IL-6), insulin-like growth factor (IGF)-1, IGF-2, and leukemia

250 notype were accompanied by altered placental insulin-like growth factor (IGF)-2 expression and insuli

251 oarray analysis, we identified and validated insulin-like growth factor (IGF)-binding protein-3 (IGFB

252 Aberrant regulation of the insulin-like growth factor (IGF)/insulin (IIS)-PI3K-AKT-

253 , including Wnt/beta-catenin, Prolactin, and insulin-like growth factor (IGF)1 signaling.

254 ance of pancreatic cancer cells by secreting insulin-like growth factors (IGF) 1 and 2, which activat

255 oming a key regulator of metabolism, whereas insulin-like growth factors (IGF)-I/II are major growth

256 The insulin-like growth factors IGF1 and IGF2 are closely re

257 A focus on reversible mechanisms identified Insulin-like growth factor (IGF1) deficiency with inadeq

258 e gene that experiences LOI is the paracrine insulin-like growth factor IGF2, which occurs commonly i

259 We show significant overexpression of insulin-like growth factors (IGFs) in association with I

260 This review discusses the role of the insulin-like growth factors (IGFs) in controlling placen

261 Insulin-like growth factors (IGFs) induce proliferation

262 ancer (insulinoma) cells that do not produce insulin-like growth factor II (IGF-II) grow slowly in pu

263 studies showed that a bilateral injection of insulin-like growth factor II (IGF-II) into the dorsal h

264 Since insulin-like growth factor II (IGF-II) receptors facilit

265 a systemic administration of the polypeptide insulin-like growth factor II (IGF-II) reverses all thes

266 st the effects of systemic administration of insulin-like growth factor II (IGF-II), a polypeptide th

267 otein of recombinant NAGLU and a fragment of insulin-like growth factor II (IGFII) was prepared for e

268 antagomir-352 up-regulated the expression of insulin-like growth factor II receptor (IGF2R), which ma

269 of the nutrient- and stress-sensing insulin/insulin-like growth factor (IIS)/TOR signalling network,

270 ile hormone, 20-hydroxyecdysone, and insulin/insulin-like growth factor-like signaling in regulating

271 barrier glial cells, activating the insulin/insulin-like growth factor pathway in underlying neural

272 s of the transforming growth factor-beta and insulin-like growth factors pathways, and extracellular

273 beta (Il1b), estrogen receptor alpha (Esr1), insulin like growth factor receptor 1 (Igf1), and glucoc

274 The type I insulin-like growth factor receptor (IGF1R) is involved

275 Inhibition of the type 1 insulin-like growth factor receptor (IGF1R) reduces the

276 the MAPK pathway, PI3Kbeta, and PI3Kalpha or insulin-like growth factor receptor 1 (IGF1R) synergisti

277 receptor (EGFR) and insulin receptor (InsR)/insulin-like growth factor receptor 1 (IGF1R), as well a

278 ative inhibition, independent of insulin and insulin-like growth factor receptor activation.

279 4 seems to exert RIBEs by acting through the insulin-like growth factor receptor DAF-2.

280 tic index, and were more highly positive for insulin-like growth factor receptor phosphorylation.

281 (OAscFab-IgG) antibody format targeting the insulin-like growth factor receptor type I (IGF-1R) and

282 y activates an insulin receptor (IR) but not insulin-like growth factor receptor-I or other receptor

283 to activate PI3K signaling downstream of the insulin-like growth factor receptor.

284 oward the insulin receptor and/or the type 1 insulin-like growth factor receptor.

285 We further demonstrate that insulin like growth factor signaling may mediate the pro

286 Down-regulation of insulin/insulin-like growth factor signaling (IIS) can increase

287 The insulin/insulin-like growth factor signaling (IIS) pathway plays

288 are linked to genes involved in the insulin/insulin-like growth factor signaling pathway that are tr

289 e to their functional linkage to insulin and insulin-like growth factor signaling pathways.

290 o DNA damage repair, cell cycle progression, insulin-like growth factor signaling, innate immunity, a

291 Insulin/insulin-like growth factor signalling (IIS) is a critica

292 ects of genetic perturbations of the insulin/insulin-like growth factor signalling pathway (IIS) on l

293 etabolic diseases and cancer are insulin and insulin-like growth factor signalling pathways.

294 e growth regulator downstream of the insulin/insulin-like growth factor/Tor pathways.

295 a key role in regulating the growth hormone/insulin-like growth factor type 1 (GH/IGF1) axis, whose

296 inases, including the highly cancer relevant insulin-like growth factor type 1 receptor (IGF-1R).

297 Insulin-like growth factor type 2 (IGF2) receptor (IGF2R

298 eceptor isoforms A and B (IR-A and IR-B) and insulin-like growth factor type I receptor (IGF-1R).

299 Dysregulation of the insulin-like growth factor type I receptor (IGF1R) has b

300 Insulin receptor and insulin-like growth factor type I receptor abundance did